Pallas Capital Advisors LLC Acquires New Position in West Pharmaceutical Services, Inc. $WST

Pallas Capital Advisors LLC purchased a new stake in West Pharmaceutical Services, Inc. (NYSE:WST) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 6,349 shares of the medical instruments supplier’s stock, valued at approximately $2,279,000.

Other institutional investors also recently bought and sold shares of the company. Bank of Nova Scotia raised its position in West Pharmaceutical Services by 337.8% in the first quarter. Bank of Nova Scotia now owns 65,323 shares of the medical instruments supplier’s stock valued at $16,373,000 after purchasing an additional 50,402 shares during the period. Hsbc Holdings PLC boosted its stake in shares of West Pharmaceutical Services by 23.3% in the fourth quarter. Hsbc Holdings PLC now owns 146,872 shares of the medical instruments supplier’s stock valued at $40,425,000 after purchasing an additional 27,745 shares during the period. Conestoga Capital Advisors LLC boosted its holdings in West Pharmaceutical Services by 6.7% in the first quarter. Conestoga Capital Advisors LLC now owns 130,970 shares of the medical instruments supplier’s stock valued at $32,826,000 after purchasing an additional 8,179 shares during the period. Renaissance Technologies LLC raised its holdings in West Pharmaceutical Services by 100.2% in the first quarter. Renaissance Technologies LLC now owns 209,660 shares of the medical instruments supplier’s stock valued at $52,549,000 after acquiring an additional 104,924 shares in the last quarter. Finally, Comerica Bank raised its holdings in shares of West Pharmaceutical Services by 31.8% in the 4th quarter. Comerica Bank now owns 56,693 shares of the medical instruments supplier’s stock valued at $15,599,000 after purchasing an additional 13,680 shares in the last quarter. 93.90% of the stock is owned by hedge funds and other institutional investors.

West Pharmaceutical Services Stock Performance

Shares of WST stock opened at $346.69 on Tuesday. West Pharmaceutical Services, Inc. has a 1 year low of $223.83 and a 1 year high of $386.00. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.12 and a current ratio of 2.82. The stock has a fifty day moving average price of $347.00 and a 200 day moving average price of $296.89. The stock has a market cap of $24.40 billion, a PE ratio of 44.39, a P/E/G ratio of 2.44 and a beta of 1.15.

West Pharmaceutical Services (NYSE:WST) last issued its quarterly earnings data on Thursday, July 23rd. The medical instruments supplier reported $2.37 EPS for the quarter, beating analysts’ consensus estimates of $2.08 by $0.29. West Pharmaceutical Services had a net margin of 16.98% and a return on equity of 20.11%. The firm had revenue of $872.30 million for the quarter, compared to analysts’ expectations of $839.98 million. During the same period in the prior year, the company earned $1.84 EPS. The firm’s revenue was up 13.8% on a year-over-year basis. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. Sell-side analysts forecast that West Pharmaceutical Services, Inc. will post 8.93 earnings per share for the current fiscal year.

West Pharmaceutical Services Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, August 5th. Stockholders of record on Wednesday, July 29th were given a $0.22 dividend. The ex-dividend date was Wednesday, July 29th. This represents a $0.88 annualized dividend and a dividend yield of 0.3%. West Pharmaceutical Services’s dividend payout ratio is currently 11.27%.

Analyst Ratings Changes

Several equities analysts have issued reports on the stock. Citigroup upped their price objective on shares of West Pharmaceutical Services from $400.00 to $412.00 and gave the company a “buy” rating in a research note on Monday, August 3rd. TD Cowen reiterated a “buy” rating on shares of West Pharmaceutical Services in a research note on Wednesday, July 15th. Zacks Research downgraded West Pharmaceutical Services from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 12th. Barclays upgraded shares of West Pharmaceutical Services from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $310.00 to $400.00 in a research report on Tuesday, June 9th. Finally, Morgan Stanley lifted their target price on shares of West Pharmaceutical Services from $325.00 to $365.00 and gave the company an “equal weight” rating in a report on Thursday, July 9th. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, West Pharmaceutical Services currently has an average rating of “Moderate Buy” and a consensus price target of $368.08.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.